Two slow-growing nontuberculous mycobacterial strains were isolated from clinical skin lesions in Jiangsu, PR China, and identified as novel species within the genus Mycobacterium . The bacterial colonies exhibited scotochromogenic pigmentation and rod-shaped morphology, and they were classified as acid-fast bacilli. Phylogenetic analysis indicated that the two strains were closely related to Mycobacterium gordonae . The two strains, X7091 T and Z3061 T , exhibited average nucleotide identity and in silico DNA–DNA hybridization values below the threshold for species delineation when compared with other type strains of M. gordonae complex. Therefore, two novel Mycobacterium species are proposed: Mycobacterium camsae sp. nov., with the type strain being X7091 T (=CGMCC 1.90336 T =JCM 37414 T ), and Mycobacterium pumcae sp. nov., with the type strain being Z3061 T (=CGMCC 1.90337 T =JCM 37415 T ).
Malassezia globosa is a major member of the human skin mycobiota and is associated with several cutaneous disorders, yet it remains unclear whether its in vitro azole susceptibility varies with disease status or anatomical site. We evaluated 55 M. globosa isolates obtained from five healthy controls, five patients with atopic dermatitis (AD), and five patients with pityriasis versicolor (PV). Isolates were collected from the forehead, posterior neck, and antecubital fossa in all participants, with additional lesional isolates from AD and PV. Minimum inhibitory concentrations (MICs) were determined for fluconazole, ketoconazole, itraconazole, posaconazole, voriconazole, and isavuconazole. Fluconazole showed the broadest MIC range (0.5–64 μg/mL), whereas posaconazole and voriconazole showed lower ranges (0.00375–0.5 μg/mL). Mixed-effects analyses of the three shared non-lesional sites detected no significant disease-group, site, or disease-by-site effects for any drug (all p > 0.05). Repeated-measures analyses within AD and PV likewise found no significant overall site effect when lesional skin was included. These exploratory data indicate substantial inter-isolate heterogeneity but no consistent association between M. globosa azole susceptibility and clinical group, anatomical site, or lesional status. Larger standardized and strain-resolved studies are warranted.
Vulvovaginal candidiasis (VVC) is a common gynecological infection, with Pichia kudriavzevii emerging as a significant pathogen due to its intrinsic fluconazole resistance and biofilm-forming capacity. This study investigates the antifungal efficacy and mechanisms of tannic acid (TA) against P. kudriavzevii, as well as its potential to reverse azole resistance across multiple Candida species with distinct resistance profiles. TA significantly inhibited P. kudriavzevii growth, surface colonization, and virulence gene expression at 3 μg/mL. Mechanistically, TA protected the human vaginal epithelial cell line VK2/E6E7 by reducing ROS levels, restoring mitochondrial membrane potential, and suppressing IL-1β and IL-18 release through modulation of the NLRP3-Caspase1-ASC axis. Furthermore, TA demonstrated synergistic activity when combined with azoles against five clinically azole-resistant Candida isolates spanning three Candida species with distinct resistance mechanisms: P. kudriavzevii (intrinsic), C. albicans (acquired), and N. glabrata (FKS-mediated). This study highlights TA as a promising natural therapeutic agent for P. kudriavzevii infections and offers a novel strategy for combating multidrug-resistant Candida through combination therapy.